Computer Aided Drug Design and Studies of Antiviral Drug against H3N2 Influenza Virus

Authors: Aditi Shukla, Ambarish S. Vidyarthi, Subir Samanta

Abstract:

The worldwide prevalence of H3N2 influenza virus and its increasing resistance to the existing drugs necessitates for the development of an improved/better targeting anti-influenza drug. H3N2 influenza neuraminidase is one of the two membrane-bound proteins belonging to group-2 neuraminidases. It acts as key player involved in viral pathogenicity and hence, is an important target of anti-influenza drugs. Oseltamivir is one of the potent drugs targeting this neuraminidase. In the present work, we have taken subtype N2 neuraminidase as the receptor and probable analogs of oseltamivir as drug molecules to study the protein-drug interaction in anticipation of finding efficient modified candidate compound. Oseltamivir analogs were made by modifying the functional groups using Marvin Sketch software and were docked using Schrodinger-s Glide. Oseltamivir analog 10 was detected to have significant energy value (16% less compared to Oseltamivir) and could be the probable lead molecule. It infers that some of the modified compounds can interact in a novel manner with increased hydrogen bonding at the active site of neuraminidase and it might be better than the original drug. Further work can be carried out such as enzymatic inhibition studies; synthesis and crystallizing the drug-target complex to analyze the interactions biologically.

Keywords: H3N2 Influenza, Neuraminidase, Oseltamiviranalogs, structure based drug designing

Digital Object Identifier (DOI): doi.org/10.5281/zenodo.1334902

References:

[1] G. WHO Fact sheet No. 211 Accessed 16 January 2009. URL: http://www.who.int/mediacentre/factsheets/fs211/en/
[2] Infection Control Today, Aug 2010, Alert on seasonal Influenza (H3N2) Virus Infections. URL:http://www.infectioncontroltoday.com/news/2010/08/cdc-issuesalert- on-seasonal-influenza-a-h3n2-virus-infections.aspx
[3] JN Varghese, Development of neuraminidase inhibitors as anti-influenza drugs. Drug Dev. Res. 46 (1999)
[4] JN Varghese, VC Epa, PM Colman, Three-dimensional structure of the complex of 4-guanidino-NeuSAc2en and influenza virus neuraminidase Prot. Sci. 4 (1995) 1081-1087.
[5] QS Du, SQ Wang, KC Chou, Analogue inhibitors by modifying oseltamivir based on the crystal neuraminidase structure for treating drug-resistant H5N1 virus, Biochem. Biophys. Res. Commun. 362 (2007) 525-531
[6] KC Chou, QS Du, DQ Wei, H Sun, Insights from modeling the 3D structure of H5N1 influenza virus neuraminidase and its binding interactions with ligands, Biochem. Biophys. Res. Commun. 344 (2006) 1048-1055
[7] Influenza Strain, H3N2, Resistant To Antivirals Amantadine and Rimantadine Main Category: Flu / Cold / SARS Article Date: 16 Jan 2006 - 0:00 PDT (Medical News Today)
[8] I Stephenson, TW Clark, M Pareek, Antiviral treatment and prevention of seasonal influenza: A comparative review of recommendations in the European Union, J. Clin. Vir. 42 (2008) 244-248.
[9] K Bauer, M Richter, P Wutzler, M Schmidtke, Different neuraminidase inhibitor susceptibilities of human H1N1, H1N2, and H3N2 influenza A viruses isolated in Germany from 2001 to 2005/06, Antivir. Res. 82 (2009) 34-41.
[10] DBM Virupakshaiah, C Kelmani, R Patil and P Hegade, Computer Aided Docking Studies on Antiviral Drugs against SARS, PWASET 24 (2007) 297-299.
[11] S. Singh, MJ Jedrzejas, GM Air, M Luo, WG Laver, WJ Brouillette, Structure - based inhibitors of Influenza Virus sialidase. A benzoic acid lead with novel interaction. J. Med. Chem. 38 (1995) 3217-3225.
[12] M Luo, GM Air, WJ Brouillette, Design of Aromatic Inhibitors of Influenza Virus Neuraminidase, J. Infect. Dis. 176 (1997) S62-S65.
[13] PM Colman, Structural basis of antigenic variation: Studies of influenza virus neuraminidase. Immunol. Cell Biol. 70 (1992) 209-214.